undamentalytics Newsletter
Sign in

Cytek Biosciences, Inc. balance sheet

At the end of fiscal 2025, Cytek Biosciences, Inc. had total assets of $462m, total liabilities of $120m and shareholders' equity of $342m. It held $90.9m in cash against $525,000 of debt: net cash of $90.3m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents165365297167999174
Receivables17304956616350
Inventory23324861444852
Total current assets209432454392396392378
Goodwill0101016171717
Total assets220463519494500462447
Deferred revenue (current)7172623252929
Total current liabilities27334956687884
Total debt0022110
Total liabilities425894101104120125
Shareholders' equity−16405426393396342322
Non-controlling interests and other (assets − liabilities − equity)194——————
Net debt (negative = net cash)−165−365−294−166−98−90−74
Shares outstanding31m—135m131m129m129m130m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CTKB vs MRVICTKB vs CYRXCTKB vs MLAB

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Cytek Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cytek Biosciences, Inc.